UBS downgrades King Pharma (NYSE: KG) from Buy to Neutral.

UBS analyst says, "While we could argue that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE